1
Email : info@xynomicpharma.com
Facebook Twitter Google+ Skype Vimeo YouTube
cropped-xynomicpharmalogo-2.jpg
  • Home
    • Privacy Policy
    • Expanded Access
  • Pipeline
  • Management
    • SCIENTIFIC ADVISORY BOARD
      • Anas Younes
      • Glenn Rice
      • Jun Guo
      • Niefang Yu
      • Pamela Munster
    • middle-level management
      • Jerry Meng
    • Y. Mark Xu
    • Jason Wu
    • Sophia Paspal
    • BING ZHAO
  • Media Center
  • Investor Relations
    • Investors
    • Events & Presentations
    • Press Releases
  • Contact Us
  • 中文 (中国)
Investor Relations
Latest News
  • wechat-image_20181027000709 Y. Mark Xu talks with CGTN (China Global TV Network) 10/26/2018
  • Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma 09/26/2019
  • Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor 09/26/2019
  • Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors 09/26/2019
  • Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors 09/01/2019
Address
  • United States: 13029 Danielson Street, Suite 120, Poway, CA 92064, USA
    China: Suite 3306, K. Wah Centre, 1010 Middle Huaihai Road, Shanghai 200031, China
Links
  • Career
  • Our Policies
Copyright © 2022 Xynomic Pharmaceuticals (Nanjing) Co., Ltd. All Rights Reserved.